Detalles de la búsqueda
1.
Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants.
Antimicrob Agents Chemother
; 66(1): e0126321, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34633853
2.
Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis).
Antimicrob Agents Chemother
; 64(7)2020 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32284384
3.
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother
; 64(3)2020 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31818823
4.
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation.
Clin Infect Dis
; 67(4): 504-512, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29617982
5.
Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae.
Antimicrob Agents Chemother
; 62(12)2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30249694
6.
Pharmacokinetics, Safety, and Tolerability Evaluation of Single and Multiple Doses of GSK3342830 in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 8(6): 754-764, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30536589
Resultados
1 -
6
de 6
1
Próxima >
>>